This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Precigen, Inc.
11/4/2026
Good afternoon, ladies and gentlemen, and welcome to the Precision Third Quarter 2026 Financial Results and Business Updates Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, November 4th, 2026. I would now like to turn the conference over to Steve Harasym. Please go ahead.
Thank you, Operator, and thank you to everyone joining us for Prestigen's third quarter 2026 financial results and business update call. Joining me today are Helen Sabzevari, our President and Chief Executive Officer, Phil Tennant, our Chief Commercial Officer, Harry Thomasian, our Chief Financial Officer, and Rutul Shah, our Chief Operating Officer. Helen will begin with our business highlights, Phil will review commercial progress, and Harry will discuss our financial results for the quarter. Rutul will be available for Q&A as well. Before we begin, I remind everyone that today's discussion will include forward-looking statements based on our current expectations and beliefs. Actual results could differ materially because of risks and uncertainties described in the forward-looking statement slide of this presentation and our most recent SEC filings. With that, I will turn the call over to Dr. Sabzevari. Helen?
Thank you, Steve, and thank you to everyone joining us today. The third quarter of 2026 represents another defining milestone for Presagen. Just over one year ago, we made the history with the FDA approval of Paxinius, the first approved treatment for adults with recurrent respiratory papillomatosis, or RRP, in more than a century of this disease. Today, We are demonstrating what that achievement means for patients, physicians, and our business. We have moved rapidly from regulatory approval to commercial success, delivering three consecutive quarters of significant revenue growth, bringing Pepsinus to major medical centers, infusion centers, and community practices across the country, achieving profitability in both the second and third quarters, and generating positive cash flow in the third quarter, ahead of our guidance, bringing in net product revenue in Q3 of 72.9 and a launch to date of $151 million. This is the definition of execution excellence. These accomplishments reflect our paradigm-shifting approach to drug development, combining differentiated science, a smart indication selection, and innovative clinical and regulatory strategies to accelerate the delivery of transformative therapies to patients. With the recent conditional approval of a competitor therapy for RRP treatment, I want to provide perspective on precision position and the continued opportunity ahead. We have always anticipated competition and incorporated it into our strategic planning, commercial modeling, and investment decisions from the outset. Our strategy was built not simply to be first, but to establish enduring leadership in RRP. And that is exactly what we have accomplished. Our leadership is built on four pillars. The first line product defined by its efficacy, safety, durability, and the ease of administration. A strong regulatory foundation, an established commercial infrastructure, and a demonstrated ability to execute. Together, these attributes have already established our position in the market, and they continue to strengthen our value proposition. First, our products. The true measure of any successful therapy is the benefit it delivers to patients. The pivotal clinical study of toxemias demonstrated an unmatched 51% complete response rate, with 18 of 35 patients requiring no surgeries during the 12 months following treatment completion. The 51% complete response primary efficacy endpoint, which is reflected in the Papsinius FDA-approved prescribing information, sets a new clinical benchmark in RRT. Similarly, Papsinius is unmatched in establishing a meaningful standard of durable complete responses for up to five years. without the need for any additional treatment. Being free of surgeries for a sustained period speaks for itself in its groundbreaking clinical benefit, which differentiates Papsinias by a wide margin. In the pivotal clinical study, Papsinias demonstrated a well-characterized safety profile with no dose-limiting toxicities and no treatment-related adverse events greater than grade 2, which is another point of differentiation. Equally important is the practicality of treatment. Pap smear is administered through a defined regimen of subcutaneous injections without the need for an external specialized device, which could also introduce device-related adverse events. Importantly, leading RRP experts continue to recognize and adopt Papsinias as the first-line standard of care treatment for adults with RRP. Second, our regulatory foundation. One of the most achievements in our development of Papsinius was securing full FDA approval in August 2025 based on the strength of the efficacy and the safety evidence presented in our BLA. This was full approval without the requirement for a post-approval confirmatory clinical trial to verify the clinical benefit. That is a significant achievement. Confirmatory clinical trials can require years of additional development, substantial financial investment, and continued regulatory uncertainty, including the risk of FDA revocation. Our approved indication, the treatment of all adults with RRP is broad. without the requirement for a minimum number of prior surgeries, enabling physicians to consider treatment based on each patient's clinical needs. This full regulatory approval, combined with our clinical evidence and broad label indication, creates a secure regulatory foundation for PAP seniors. Third, Our commercial leadership. Being first to market gave us an important opportunity. Our commercial strategy and execution have transformed that opportunity into a significant first mover advantage. And the result speaks for itself. As of today's call, well over 500 patients have become treatment of Paximius, and well over 300 of them have completed treatment. This rapid adaption in a rare disease is a powerful demonstration of the demand for Paximius and the effectiveness of our commercial strategy. Phil will provide more details on these subjects but we have established our leadership position in RRP and we continue to rapidly scale our commercial business. Finally, our ability to execute. Pratican achieved full FDA approval of Papsinias in less than five years from IND, demonstrating our ability to translate innovative science into an approved medicine with remarkable speed. We have demonstrated our ability to execute across the entire development and commercialization continuum, from innovative science to regulatory approval to a growing profitable commercial business. Today, with more than a year of commercial experience, a strong physician adoption, and enthusiastic market reception, we have substantially strengthened that position to sustain and grow our significant first mover advantage. With that, I will turn the call over to Phil for a closer look at our commercial progress. Phil?
You're reading a preview of the PGEN Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing